BACKGROUND: Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major cardiovascular disease risk factor. Genetic factors are an important determinant of LDL-C levels. METHODS: To identify single nucleotide polymorphisms associated with LDL-C and subclinical coronary atherosclerosis, we performed a genome-wide association study of LDL-C in 841 asymptomatic Amish individuals aged 20 to 80 years, with replication in a second sample of 663 Amish individuals. We also performed scanning for coronary artery calcification (CAC) in 1018 of these individuals. RESULTS: From the initial genome-wide association study, a cluster of single nucleotide polymorphisms in the region of the apolipoprotein B-100 gene (APOB) was strongly associated with LDL-C levels (P < 10(-68)). Additional genotyping revealed the presence of R3500Q, the mutation responsible for familial defective apolipoprotein B-100, which was also strongly associated with LDL-C in the replication sample (P < 10(-36)). The R3500Q carrier frequency, previously reported to be 0.1% to 0.4% in white European individuals, was 12% in the combined sample of 1504 Amish participants, consistent with a founder effect. The mutation was also strongly associated with CAC in both samples (P < 10(-6) in both) and accounted for 26% and 7% of the variation in LDL-C levels and CAC, respectively. Compared with noncarriers, R3500Q carriers on average had LDL-C levels 58 mg/dL higher, a 4.41-fold higher odds (95% confidence interval, 2.69-7.21) of having detectable CAC, and a 9.28-fold higher odds (2.93-29.35) of having extensive CAC (CAC score ≥400). CONCLUSION: The R3500Q mutation in APOB is a major determinant of LDL-C levels and CAC in the Amish.
BACKGROUND: Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major cardiovascular disease risk factor. Genetic factors are an important determinant of LDL-C levels. METHODS: To identify single nucleotide polymorphisms associated with LDL-C and subclinical coronary atherosclerosis, we performed a genome-wide association study of LDL-C in 841 asymptomatic Amish individuals aged 20 to 80 years, with replication in a second sample of 663 Amish individuals. We also performed scanning for coronary artery calcification (CAC) in 1018 of these individuals. RESULTS: From the initial genome-wide association study, a cluster of single nucleotide polymorphisms in the region of the apolipoprotein B-100 gene (APOB) was strongly associated with LDL-C levels (P < 10(-68)). Additional genotyping revealed the presence of R3500Q, the mutation responsible for familial defective apolipoprotein B-100, which was also strongly associated with LDL-C in the replication sample (P < 10(-36)). The R3500Q carrier frequency, previously reported to be 0.1% to 0.4% in white European individuals, was 12% in the combined sample of 1504 Amish participants, consistent with a founder effect. The mutation was also strongly associated with CAC in both samples (P < 10(-6) in both) and accounted for 26% and 7% of the variation in LDL-C levels and CAC, respectively. Compared with noncarriers, R3500Q carriers on average had LDL-C levels 58 mg/dL higher, a 4.41-fold higher odds (95% confidence interval, 2.69-7.21) of having detectable CAC, and a 9.28-fold higher odds (2.93-29.35) of having extensive CAC (CAC score ≥400). CONCLUSION: The R3500Q mutation in APOB is a major determinant of LDL-C levels and CAC in the Amish.
Authors: Marian Beekman; Bastiaan T Heijmans; Nicholas G Martin; Nancy L Pedersen; John B Whitfield; Ulf DeFaire; G Caroline M van Baal; Harold Snieder; George P Vogler; P Eline Slagboom; Dorret I Boomsma Journal: Twin Res Date: 2002-04
Authors: Huichun Xu; Kathleen A Ryan; Thomas J Jaworek; Lorraine Southam; Jeffrey G Reid; John D Overton; Aris Baras; Marja K Puurunen; Eleftheria Zeggini; Simeon I Taylor; Alan R Shuldiner; Braxton D Mitchell Journal: Diabetes Date: 2017-04-20 Impact factor: 9.461
Authors: May E Montasser; Elizabeth A O'Hare; Xiaochun Wang; Alicia D Howard; Rebecca McFarland; James A Perry; Kathleen A Ryan; Kenneth Rice; Cashell E Jaquish; Alan R Shuldiner; Michael Miller; Braxton D Mitchell; Norann A Zaghloul; Yen-Pei C Chang Journal: Circulation Date: 2018-09-25 Impact factor: 29.690
Authors: Braxton D Mitchell; Gurmannat Kalra; Kathleen A Ryan; Man Zhang; Carole Sztalryd; Nanette I Steinle; Simeon I Taylor; Soren Snitker; Joshua P Lewis; Michael Miller; Alan R Shuldiner; Huichun Xu Journal: J Clin Lipidol Date: 2018-11-20 Impact factor: 4.766
Authors: Nora Kory; Susanne Grond; Siddhesh S Kamat; Zhihuan Li; Natalie Krahmer; Chandramohan Chitraju; Ping Zhou; Florian Fröhlich; Ivana Semova; Christer Ejsing; Rudolf Zechner; Benjamin F Cravatt; Robert V Farese; Tobias C Walther Journal: J Lipid Res Date: 2016-11-11 Impact factor: 5.922
Authors: Salma E El-Habashy; Alaa M Nazief; Chris E Adkins; Ming Ming Wen; Amal H El-Kamel; Ahmed M Hamdan; Amira S Hanafy; Tori O Terrell; Afroz S Mohammad; Paul R Lockman; Mohamed Ismail Nounou Journal: Pharm Pat Anal Date: 2014-05
Authors: Laura M Yerges-Armstrong; Haiqing Shen; Kathleen A Ryan; Elizabeth A Streeten; Alan R Shuldiner; Braxton D Mitchell Journal: J Clin Endocrinol Metab Date: 2013-10-08 Impact factor: 5.958